Chica­go AI drug dis­cov­ery shop Evozyne nabs $81M in bid to make new pro­teins

Chica­go start­up Evozyne has raised $81 mil­lion fol­low­ing a gen­er­a­tive AI col­lab­o­ra­tion with Nvidia an­nounced ear­li­er this year.

The three-year-old start­up is cre­at­ing new pro­teins to use for ther­a­peu­tics and car­bon cap­ture and has al­ready part­nered with Take­da. Evozyne an­nounced in April 2022 that it would help cre­ate pro­teins for the Japan­ese phar­ma to po­ten­tial­ly use in gene ther­a­pies, span­ning up to four rare dis­ease tar­gets. But it’s al­so look­ing to de­vel­op its own pro­grams.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.